Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 nov. 2014 05h44 HE | Source: Bionor Pharma

UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV

OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR) Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated ...
17 nov. 2014 08h01 HE | Source: Bionor Pharma

Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV

OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR) Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated ...
11 févr. 2014 09h27 HE | Source: Bionor Pharma

Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases

OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...